COMPANY PROFILE

Seahorse Bioscience

Explore full profile

Seahorse Bioscience - Making Cell Metabolism Even Easier

Billerica, United StatesFounded 2000Biotech & Life Sciences

Valuation $100–250M Last recorded · 2015

Revenue $10–50M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Seahorse Bioscience

Seahorse Bioscience, now part of Agilent Technologies, is a prominent player in the life sciences sector, specializing in advanced cell analysis technologies. The company focuses on developing and manufacturing innovative instruments and software that enable researchers to measure cellular bioenergetics in real-time. This means they help scientists understand how cells produce and use energy, which is crucial for studying cell function, disease mechanisms, and potential treatments.

Seahorse Bioscience serves a diverse range of clients, including academic researchers, pharmaceutical companies, and biotechnology firms. These clients use Seahorse's tools to gain insights into cellular metabolism, which can lead to breakthroughs in areas such as cancer research, drug development, and personalized medicine.

Operating in the highly competitive life sciences market, Seahorse Bioscience distinguishes itself through its cutting-edge technology and comprehensive solutions. Their product lineup includes the Seahorse XF Analyzers, which are renowned for their ability to provide real-time measurements of cellular respiration and glycolysis. Additionally, Seahorse offers a variety of assay kits and software solutions that streamline the process of designing, running, and analyzing experiments.

The business model of Seahorse Bioscience revolves around the sale of its high-performance instruments and consumable assay kits. They also generate revenue through software licenses and training programs. For instance, their Virtual Instructor Led Training from Agilent University offers the benefits of live lab training with the convenience of online education, ensuring that clients can maximize the utility of Seahorse's products.

In summary, Seahorse Bioscience, as part of Agilent Technologies, provides comprehensive cell analysis solutions that empower researchers to uncover critical insights into cellular function and disease. Their innovative products and dedicated support services make them a valuable partner in the life sciences research community.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2000
Headquarters: Billerica, United States
Employees: 5
Open positions: None listed
Dealroom signal: 23.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Mar 2009
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Sep 2015	$235M	$235M	Agilent	—
GROWTH EQUITY VC✓Equity / VC	Apr 2013	$11M	—	Undisclosed	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Seahorse Bioscience website traffic

Latest recorded traffic for Seahorse Bioscience is 240 monthly website visits, down 4% over the last three months.

Latest monthly visits240 3-month web change-4%

Monthly website visitsApr 2016–Apr 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed	—	$1.1M	$4.4M
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed